Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SVRA - Savara Inc

IEX Last Trade
3.23
-0.035   -1.084%

Share volume: 19,319
Last Updated: Thu 26 Dec 2024 08:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$3.26
-0.04
-1.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 7%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.54%
1 Month
-7.51%
3 Months
-24.53%
6 Months
-16.67%
1 Year
-33.05%
2 Year
113.33%
Key data
Stock price
$3.23
P/E Ratio 
0.00
DAY RANGE
$3.14 - $3.27
EPS 
$0.00
52 WEEK RANGE
$3.00 - $5.70
52 WEEK CHANGE
-$33.61
MARKET CAP 
702.845 M
YIELD 
N/A
SHARES OUTSTANDING 
164.601 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,228,464
AVERAGE 30 VOLUME 
$1,466,027
Company detail
CEO: Matthew Pauls
Region: US
Website: savarapharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Savara Inc. focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor. The company is headquartered in Austin, Texas.

Recent news